Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01653392 · ClinicalTrials.gov registry record
BioThrax® (Anthrax) Vaccine in Pregnancy Registry
A clinical trial, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- 98
- Enrollment target
NCT01653392: Completed study, sponsored by Emergent BioSolutions.
NCT01653392 is a clinical trial that has completed, run by Emergent BioSolutions. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01653392 has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if inadvertent receipt of the BioThrax vaccine during pregnancy is independently associated with adverse maternal, pregnancy, or infant health outcomes.
Primary Outcome
Pregnancy outcomes measured include live birth, still birth, spontaneous abortion, elective termination, ectopic pregnancy, or molar pregnancy Note: Twin or higher order multiple pregnancies may have more than one outcome.
Interventions
- BIOLOGICAL Observational Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2012-07 |
| Est. Completion | 2020-02 |
What the finished NCT01653392 record still lists
NCT01653392 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Observational Intervention is the first listed.
NCT01653392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01653392 about?
NCT01653392 is a clinical study titled "BioThrax® (Anthrax) Vaccine in Pregnancy Registry". The purpose of this study is to determine if inadvertent receipt of the BioThrax vaccine during pregnancy is independently associated with adverse maternal, pregnancy, or infant health outcomes.
What is the current status of trial NCT01653392?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2012-07. Estimated completion is 2020-02.
What interventions are being tested in trial NCT01653392?
The interventions under investigation include: Observational Intervention (BIOLOGICAL).
Who is sponsoring clinical trial NCT01653392?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia